Pushed By Rising Costs And Slow Approvals, India’s Dishman Set To Retreat From China
This article was originally published in PharmAsia News
Executive Summary
Dishman’s move follows similar moves from Indian peers like Dr. Reddy’s and Ranbaxy, which have also soured on the Chinese market.